Be part of the knowledge.™

Oncology and Hematology

9

LikeLikedUnlike

Episodes 1-15 of 25

Operational Considerations for Bispecific T-Cell Engager Therapies
Medical Industry Feature
Operational Considerations for Bispecific T-Cell Engager Therapies
- Jennifer Caudle, DO
  Peer
- David M. Waterhouse, MD, MPH
  Peer
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
Medical Industry Feature
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
- Brian Gill, M.D.
  Peer
Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
Project Oncology®
Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
- Jennifer Caudle, DO
  Peer
- Ross Camidge, MD, PhD
  Peer
- Jonathan Goldman, MD
  Peer
Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing
Medical Industry Feature
Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing
- Joel Gabre, M.D, MPH
  Peer
Managing Capillary Leak Syndrome: Early Recognition and Intervention in BPDCN Care
Medical Industry Feature
Managing Capillary Leak Syndrome: Early Recognition and Intervention in BPDCN Care
- Jennifer Caudle, DO
  Peer
- James McCloskey II, MD
  Peer
Advancing Care in Pretreated HR+/HER2- mBC
Medical Industry Feature
Advancing Care in Pretreated HR+/HER2- mBC
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Aashini Master, DO
  Peer
- Neil M. Iyengar, MD
  Peer
advertisement
Supportive Care in Patients with Pretreated HR+/HER2- mBC
Medical Industry Feature
Supportive Care in Patients with Pretreated HR+/HER2- mBC
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Aashini Master, DO
  Peer
- Neil M. Iyengar, MD
  Peer
What Is Macrophage Activation Syndrome?
Medical Industry Feature
What Is Macrophage Activation Syndrome?
- Daniella Schwartz, MD
  Peer
- Randy Cron, MD, PhD
  Peer
The Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
Medical Industry Feature
The Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
Ph+ CML and Treatment Adherence: Rethinking Nilotinib Formulations and Fasting Restrictions
Medical Industry Feature
Ph+ CML and Treatment Adherence: Rethinking Nilotinib Formulations and Fasting Restrictions
- Jennifer Caudle, DO
  Peer
- Michael J. Mauro, MD
  Peer
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
Medical Industry Feature
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
- Mateo Mejia Saldarriaga, M.D.
  Peer
RAI-R DTC: Explore This Pivotal Study Data
Medical Industry Feature
RAI-R DTC: Explore This Pivotal Study Data
- Mark Lupo, MD, FACE, ECNU
  Peer
advertisement
Patient Stories: Andrew’s Journey with Indolent Systemic Mastocytosis (ISM)
Medical Industry Feature
Patient Stories: Andrew’s Journey with Indolent Systemic Mastocytosis (ISM)
Mapping CLL Treatment Endpoints: PFS and TTNT in Fixed vs Continuous Therapy
Clinician's Roundtable
Mapping CLL Treatment Endpoints: PFS and TTNT in Fixed vs Continuous Therapy
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Carter Davis, MD
  Peer
Understanding the Advances and Current Challenges in RRMM Therapy
Clinician's Roundtable
Understanding the Advances and Current Challenges in RRMM Therapy
- Rahul Banerjee, MD, FACP
  Peer
- Charles Turck, PharmD, BCPS, BCCCP
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended